Search

everythinglearnresearchcommunity

for

Search:↓

RU58841 may still be potent after being left unopened for four months if protected from light and air. A user reported hair improvement using RU58841 with minoxidil, without major shedding, over 2.5 years.

Spironolactone is more potent and lowers testosterone and DHT, while dutasteride only impacts DHT. For female hair loss, checking hormones and considering treatments like oral minoxidil, spironolactone, or topical minoxidil is recommended.

The conversation discusses patient updates on hair loss treatment with Verteporfin after five months, as reported by Dr. Blake Bloxham. Patients voluntarily sent their progress pictures to Dr. Bloxham.

A dermatologist advised a patient to stop taking finasteride (fin) after turning 40 due to potential risk of aggressive prostate cancer. The patient and others in the conversation debated this advice, discussing the relationship between finasteride, prostate cancer, and hair loss, and considering alternatives like topical finasteride.

The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.

A user suggests making a potent sulforaphane topical to degrade DHT and promote hair growth. Another user notes that sulforaphane's low molecular weight might also lower systemic DHT.

PP405 is expected to be more expensive than finasteride and minoxidil initially due to patent protection, but not as costly as life-saving medications like Ozempic. The price may decrease after the patent expires, but initially, it might be around $100 per month, making it potentially unaffordable for many.

The post discusses a new hair loss treatment involving an improved pyri formula that has shown promising results, including thicker hair and a restored hairline, with minimal side effects. The author seeks investors to collaborate with Kintor or acquire the pyri patent, offering equity rewards and complimentary samples for verification.

Hair transplants in Turkey can be risky due to unqualified practitioners and high patient volumes, but some clinics offer good results if researched properly. It's crucial to choose a reputable clinic and doctor, as experiences vary widely.

A user discusses the potential of caffeine and DMG in shampoo for treating hair loss, citing a pending patent and personal plans to test it. They find it more convenient than using minoxidil, tretinoin, and microneedling.

A doctor advised against taking finasteride after a hair transplant, suggesting the patient had reached their final balding pattern, but many users disagreed, recommending medications like minoxidil and finasteride to prevent further hair loss. The consensus was to seek a second opinion, as the advice seemed financially motivated rather than medically sound.

Retinol is not effective alone for hair loss; tretinoin is more potent and sometimes mixed with minoxidil. Retinoids do not stop hair loss, and finasteride or dutasteride is necessary for that.

KX-826 failed Phase III trials due to high placebo effects, patient compliance issues, COVID-19 side effects, and detection method deviations. KX-826 is now marketed as a cosmetic and approved for combination with Minoxidil.

The conversation is about whether Saw Palmetto, which has similar but less potent effects to Finasteride, could cause the same side effects due to lowering DHT levels. The user is considering oral Saw Palmetto as an alternative to Finasteride for hair loss treatment.

A 16-year-old started using topical finasteride, minoxidil, and dermapen for hair regrowth, along with natural DHT blockers. Advice given includes being patient and considering waiting until 18-21 to use finasteride.

The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

Pyrilutamide, a possible hair loss treatment, ceasing to be traded due to patent laws; and the hope that this indicates it may be a legitimate treatment.

First people receive Pyrilutamide on March 19th, 2022 for hair loss treatment. Users discuss obtaining the drug, its patent, and potential group buys.

The conversation discusses an interview with Dr. Tsuji about hair follicle stem cell multiplication and the financial challenges of starting human clinical trials. It also mentions the need for funding to secure a patent for a protein that promotes hair growth.

Minoxidil can cause initial hair shedding, but it's a sign the treatment is working. Users suggest combining it with finasteride and being patient, as hair often regrows after the shedding phase.

The user has been using minoxidil for almost 6 months and finasteride for almost 4 months, experiencing significant shedding and minimal stabilization. They are considering switching to dutasteride if no improvements are seen and are advised to be patient, as results may take up to 2 years.

A user shared their experience with two hair transplants in Istanbul, highlighting the importance of choosing clinics with a low doctor-to-patient ratio, ISHRS membership, thorough consultations, and reliable aftercare. They emphasized the significance of PRP shots post-procedure and advised careful selection of clinics, especially for crown procedures, due to limited donor area opportunities.

Shiseido's S-DSC hair regenerative treatment in Japan focuses on improving existing hair by thickening miniaturized follicles, not creating new ones. There is limited patient feedback and long-term data available.

The user is experiencing hair loss and is using treatments like finasteride, minoxidil, and hormone replacement therapy (estradiol enanthate injections) to address it. They are advised to be patient with the treatments and consider using a dermapen for microneedling.

Hair transplantation involves a detailed consultation, preparation, and a long-term recovery process with stages like initial shedding and gradual new hair growth over months. Setting realistic expectations is crucial for patient satisfaction.

A 20-year-old male experiencing hair loss is using topical finasteride and recently added dutasteride but is still losing hair and considering giving up. Suggestions include being patient, giving dutasteride more time, trying oral finasteride, adding minoxidil, and considering other treatments like low-level laser therapy.

The user is experiencing increased hair shedding after starting finasteride at 0.25mg daily, and others suggest this is normal and will improve over time. Recommendations include continuing the current dose, considering minoxidil, and being patient as shedding can last several months before improvement.

Dermatologists use treatments like oral minoxidil, finasteride, and RU58841 for male-pattern baldness, considering side effects and patient preferences. Photobiomodulation is noted as mildly effective but costly, while PRP is debated for its effectiveness compared to microneedling.